J.ophthalmol.(Ukraine).2022;4:49-57.

Pdf

http://doi.org/10.31288/oftalmolzh202244957

Received: 19.05.2022; Accepted: 14.07.2022; Published on-line: 24.08.2022


Recurrent ocular toxoplasmosis infection in a patient with a selective deficiency of NK T-cells and cytotoxic СD8+ T-cells associated with a genetic folate cycle deficiency

D. V. Maltsev,  O. O. Hurzhii 

1 Research Institute of Experimental and Clinical Medicin, Bogomolets National Medical University; Kyiv (Ukraine)

2 Visium Clinic; Kyiv (Ukraine)

TO CITE THIS ARTICLE: Maltsev DV,  Hurzhii OO. Recurrent ocular toxoplasmosis infection in a patient with a selective deficiency of NK T-cells and cytotoxic СD8+ T-cells associated with a genetic folate cycle deficiency. J.ophthalmol.(Ukraine).2022;4:49-57.     http://doi.org/10.31288/oftalmolzh202244957

 

This paper reports a case of recurrent toxoplasmic chorioretinitis in a patient with cellular immunodeficiency. A 37-year-old male presented to an ophthalmologist with complaints of reduced visual acuity and discomfort in his left eye. He had a history of at least two episodes of acute posterior uveitis without identifying the cause of inflammation. An ophthalmoscopic evaluation revealed a scar in the right retina and signs of acute vitritis and chorioretintis surrounding a scar in the left retina. Paired serology confirmed a diagnosis of toxoplasmosis. A deficiency of NK T-cells and cytotoxic СD8+ T-cells was noted, but there was no evidence of secondary immunosuppression. The Primary Immunodeficiency (PID) panel providing sequencing of 208 genes did not find a disease. A test for genetic folate cycle deficiency was conducted due to persistent hyperhomocysteinemia. The genetic testing identified two pathogenic polymorphisms in the genes coding for folic acid cycle enzymes (heterozygous MTHFR A1298C and homozygous MTRR A66G), which was believed to be associated with a cellular immunity, taking into account the data on immunosuppression and opportunistic infections in the presence of a genetic folate cycle deficiency.

The following treatment was administered: spiramycin, 3.0 mln units orally daily for 14 days, to inhibit toxoplasma; recombinant human alpha2 interferon (3.0 mln units intramuscularly every other day for a month) and oxodihydroacridinylacetate sodium 2.0 mln units intramuscularly every other day for a month, with switching between this agent and interferon, to compensate for a deficiency of NK T-cells and СD8+ T-cells; and daily peribulbar injection of betamethasone 4 mg/mL for 3 days. The first signs of improved visual acuity were seen at day 8, and a complete restoration of vision in the left eye was achieved by the end of one month of combination therapy. In addition, the patient received three one-month courses of alpha2 interferon for compensation of cellular immunodeficiency over two years which prevented a recurrence of toxoplasmosis.

Keywords: toxoplasmic chorioretinitis, vitritis, immunodeficiency, immunotherapy

 

References

1.Fabiani S, Caroselli C, Menchini M, et al. Ocular toxoplasmosis, an overview focusing on clinical aspects. Acta Trop. 2022 Jan;225:106180.

Crossref  PubMed

2.Karanovic D, Michelow IC, Hayward AR, et al. Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase delta Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies. Front Immunol. 2019 Feb 14;10:77.

Crossref  PubMed

3.de-la-Torre A, Gómez-Marín J. Disease of the Year 2019: Ocular Toxoplasmosis in HIV-infected Patients. Ocul Immunol Inflamm. 2020 Oct 2;28(7):1031-1039.

Crossref  PubMed 

4.Srivastava S, Kundu A, Sivakumar H, et al. A case of Toxoplasma gondii and Strongyloides stercoralis coinfection in an immunocompromised patient. Infect. Disord Drug Targets. 2022 Feb 18. Online ahead of print.

Crossref  PubMed

5.Parasram M., Arevalo-Perez J. Cerebral toxoplasmosis in a patient with multiple myeloma. Surg Neurol Int. 2022 May 6;13:191.

Crossref  PubMed

6.Gioia LV, Bonsall D, Moffett K, et al. Bilateral maculopathy in a patient with ataxia telangiectasia. J AAPOS. 2016 Feb;20(1):85-8.

Crossref  PubMed

7.Nelwan EJ, Shakinah S, Clarissa G, et al. Rare cardiac complication of toxoplasmosis in immunocompetent host. IDCases. 2022 Jun 15; 29: e01533.

Crossref  PubMed

8.Stokkermans TJ, Havens SJ. Toxoplasma Retinochoroiditis. [Updated 2022 Mar 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.

9.Zhang K, Lin G, Han Y, Li J. Serological diagnosis of toxoplasmosis and standardization. Clin Chim Acta. 2016 Oct 1;461:83-9.

Crossref  PubMed 

10.Chan Y, Martin D, Mace KE, et al. Multiplex Serology for Measurement of IgG Antibodies Against Eleven Infectious Diseases in a National Serosurvey: Haiti 2014-2022. Front Public Health. Jun 9; 10: 897013.

Crossref  PubMed

11.Borges HDS, Oliveira-Scussel ACM, Oliveira ÂMM, et al. Comparative Detection of Immunoglobulin Isotypes and Subclasses against Toxoplasma gondii Soluble Antigen in Serum and Colostrum Samples from Puerperal Women. Int J Environ Res Public Health. 2022 Jun 29; 19(13): 7953.

Crossref  PubMed

12.Babekir A., Mostafa S., Minor R.C. et al. The Association of Toxoplasma gondii IgG and Liver Injury in US Adults. Int J Environ Res Public Health. 2022 Jun 19;19(12):7515.

Crossref  PubMed

13.Combe CL, Curiel TJ, Moretto MM, Khan IA. NK cells help to induce CD8(+)-T-cell immunity against Toxoplasma gondii in the absence of CD4(+) T cells. Infect Immun. 2005 Aug;73(8):4913-21.

Crossref  PubMed

14.Khan I.A., Moretto M. Immune responses to Toxoplasma. Curr Opin Immunol. 2022 Jul 1 ;77: 102226.

Crossref  PubMed

15.Sana M, Rashid M, Rashid I, et al. Immune response against toxoplasmosis-some recent updates RH: Toxoplasma gondii immune response. Int J Immunopathol Pharmacol. Jan-Dec 2022; 36: 3946320221078436.

Crossref  PubMed

16.Sasai M, Yamamoto M. Anti-Toxoplasma host defense systems and the parasitic counterdefense mechanisms. Parasitol Int. 2022 Aug;89:102593.

Crossref  PubMed 

17.Li WX, Cheng F, Zhang AJ, et al. Folate Deficiency and Gene Polymorphisms of MTHFR, MTR and MTRR Elevate the Hyperhomocysteinemia Risk. Clin Lab. 2017 Mar 1;63(3):523-533.Crossref 

18.Zhang L, Yuan XF, Li Q, et al. Correlation between Serum Homocysteine Level, MTHFR Gene Polymorphism and Patients with Hematological Diseases Complicated with Coronary Heart Disease. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Feb;30(1):305-309

19.Van der Weyden MB, Hayman RJ, et al. Folate-deficient human lymphoblasts: changes in deoxynucleotide metabolism and thymidylate cycle activities. Eur J Haematol. 1991 Aug;47(2):109-14.

Crossref  PubMed

20.Partearroyo T, Úbeda N, Montero A. Vitamin B(12) and folic acid imbalance modifies NK cytotoxicity, lymphocytes B and lymphoprolipheration in aged rats. Nutrients. 2013 Nov 26;5(12):4836-48.

Crossref  PubMed

21.Courtemanche C, Elson-Schwab I, Mashiyama ST. Folate deficiency inhibits the proliferation of primary human CD8+ T lymphocytes in vitro. J Immunol. 2004 Sep 1;173(5):3186-92. 

Crossref  PubMed

22.Abe I, Shirato K, Hashizume Y. Folate-deficiency induced cell-specific changes in the distribution of lymphocytes and granulocytes in rats. Environ Health Prev Med. 2013 Jan;18(1):78-84.

Crossref  PubMed

23.Troen AM, Mitchell B, Sorensen B. Unmetabolized folic acid in plasma is associated with reduced natural killer cell cytotoxicity among postmenopausal women. J Nutr. 2006 Jan;136(1):189-94.

Crossref  PubMed

24.Bhatnagar N, Wechalekar A, McNamara C. Pancytopenia due to severe folate deficiency. Intern Med J. 2012 Sep;42(9):1063-4.

Crossref  PubMed

25.Maltsev DV, Gorbenko VYu. [HSV-2-associated transverse sacral myelitis in a patient with selective natural killer cell deficiency: a case report]. Ukr Neurol Zh. 2018; №2: 74–80. Ukrainian.

Crossref 

26.Maltsev DV. Features of folate cycle disorders in children with ASD. Bangladesh J Med Sci. 2020; Vol. 19(4): 737–742.

Crossref

27.Maltsev DV. [The results of the study of the microbial spectrum in children with autism spectrum disorders associated with genetic deficiency of the folate cycle]. Choloviche zdorov’ia, genderna ta psyhosomatychna medycyna. 2021; № 1-2: 26–39. Ukrainian.

Crossref 

28.Yamagiwa S, Matsuda Y, Ichida T, et al. Sustained response to interferon-alpha plus ribavirin therapy for chronic hepatitis C is closely associated with increased dynamism of intrahepatic natural killer and natural killer T cells. Hepatol Res. 2008 Jul;38(7):664-72.

Crossref  PubMed 

29.Okumura A, Ishikawa T, Maeno T, et al. Changes in natural killer T cells subsets during therapy in type C hepatitis and hepatocellular carcinoma. Hepatol Res. 2005 Aug;32(4):213-7. 

Crossref  PubMed

30.Maltsev DV. [New discoveries in the mechanisms of interferon-dependent control of latent alpha-herpes virus in sensory ganglia and the experience of using an inducer of interferon overin for the restoration of such control]. Choloviche zdorov’ia, genderna ta psyhosomatychna medycyna. 2018; № 2: 19–32. Ukrainian.

Crossref 

31.Skariah S, Sultan AA., Mordue DG. IFN-induced cell-autonomous immune mechanisms in the control of intracellular protozoa. Parasitol Res. 2022 Jun;121(6):1559-1571.

Crossref  PubMed

32.Maltsev DV, Hurzhii OO. Toxoplasma chorioretinitis in primary myeloperoxidase MPO deficiency: A case report. J Ophthalmol (Ukraine). 2019; Vol. 4: 75-81.

Crossref 

33.Maltsev DV, Hurzhii OO. ANA-associated uveitis in the presence of reactivated HHV-7 infection in a patient with MBL deficiency. J Ophthalmol. (Ukraine). 2020; Vol. 6 (497): 64–9.

Crossref 

34.Maltsev DV. A case of persistent recurrent herpes zoster ophthalmicus in a patient with primary mannose binding lectin deficiency. J Ophthalmol (Ukraine).  2021; Vol. 6 (503): 64–68.

Crossref

35.Shachor J, Shneyour A., Radnay J. et al. Toxoplasmosis in a patient with common variable immunodeficiency. Am J Med Sci. May-Jun 1984;287(3):36-8.

Crossref  PubMed

36.Liu X, Zhou K, Yu D, et al. A delayed diagnosis of X-linked hyper IgM syndrome complicated with toxoplasmic encephalitis in a child: A case report and literature review. Medicine (Baltimore). 2017 Dec;96(49):e8989.

Crossref  PubMed 

37.Le Deist F, Hivroz C, Partiseti M, et al. A primary T-cell immunodeficiency associated with defective transmembrane calcium influx. Blood. 1995 Feb 15;85(4):1053-62.

Crossref  PubMed

38.Yong PF, Post FA, Gilmour KC, et al. Cerebral toxoplasmosis in a middle-aged man as first presentation of primary immunodeficiency due to a hypomorphic mutation in the CD40 ligand gene. J Clin Pathol. 2008 Nov;61(11):1220-2.

Crossref  PubMed

39.Sasson SC, Davies S, Chan R, et al. Cerebral toxoplasmosis in a patient with myasthenia gravis and thymoma with immunodeficiency/Good's syndrome: a case report. BMC Infect Dis. 2016 Aug 30;16(1):457.

Crossref  PubMed

40.Kalogeropoulos D, Sakkas H, Mohammed B, et al. Ocular toxoplasmosis: a review of the current diagnostic and therapeutic approaches. Int Ophthalmol. 2022 Jan;42(1):295-321.

Crossref  PubMed

41.McDermott DH, Heusinkveld LE, Zein WM, et al. Case Report: Ocular toxoplasmosis in a WHIM syndrome immunodeficiency patient. F1000Res. 2019 Jan 2;8:2.

Crossref  PubMed

42.Meyer L, Magierowska M, Hubert JB, et al. CCR5 delta32 deletion and reduced risk of toxoplasmosis in persons infected with human immunodeficiency virus type 1. The SEROCO-HEMOCO-SEROGEST Study Groups. J Infect Dis. 1999 Sep;180(3):920-4.

Crossref  PubMed

 

Disclosures 

Corresponding Author: Maltsev D.V., email: dmaltsev@ukr.net

Conflict of Interests: The author certifies that there is no conflict of interest that could influence his opinion regarding the subject matter or materials described and discussed in this manuscript.